Literature DB >> 30558693

Potential clinical applications of circulating cell-free DNA in ovarian cancer patients.

Ana Barbosa1, Ana Peixoto2, Pedro Pinto1, Manuela Pinheiro1, Manuel R Teixeira1.   

Abstract

Circulating cell-free DNA (cfDNA) consists of small fragments of DNA that circulate freely in the bloodstream. In cancer patients, a fraction of cfDNA is derived from tumour cells, therefore containing the same genetic and epigenetic alterations, and is termed circulating cell-free tumour DNA. The potential use of cfDNA, the so-called 'liquid biopsy', as a non-invasive cancer biomarker has recently received a lot of attention. The present review will focus on studies concerning the potential clinical applications of cfDNA in ovarian cancer patients.

Entities:  

Keywords:  Cell-free circulating DNA; cell-free circulating tumour DNA; diagnosis; liquid biopsy; ovarian cancer; prognosis; therapy monitoring

Mesh：

Substances：

Year:  2018        PMID： 30558693     DOI： 10.1017/erm.2018.5

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN： 1462-3994            Impact factor:   5.600


  7 in total

1.  Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.

Authors:  Aiko Ogasawara; Taro Hihara; Daisuke Shintani; Akira Yabuno; Yuji Ikeda; Kenji Tai; Keiichi Fujiwara; Keisuke Watanabe; Kosei Hasegawa
Journal:  Cancer Res Treat       Date:  2020-05-06       Impact factor: 4.679

2.  Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer.

Authors:  Victoria Tserpeli; Dimitra Stergiopoulou; Dora Londra; Lydia Giannopoulou; Paul Buderath; Ioanna Balgkouranidou; Nikolaos Xenidis; Christina Grech; Eva Obermayr; Robert Zeillinger; Kitty Pavlakis; Theodoros Rampias; Stylianos Kakolyris; Sabine Kasimir-Bauer; Evi S Lianidou
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

Review 3.  Potential clinical utility of liquid biopsies in ovarian cancer.

Authors:  Jie Wei Zhu; Parsa Charkhchi; Mohammad R Akbari
Journal:  Mol Cancer       Date:  2022-05-11       Impact factor: 41.444

4.  Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer.

Authors:  Xiaoxiang Jie; Ming Du; Meng Zhang; Xiayu Jin; Qingqing Cai; Congjian Xu; Xiaoyan Zhang
Journal:  Exp Ther Med       Date:  2022-06-30       Impact factor: 2.751

Review 5.  ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors.

Authors:  Dirk Timmerman; François Planchamp; Tom Bourne; Chiara Landolfo; Andreas du Bois; Luis Chiva; David Cibula; Nicole Concin; Daniela Fischerova; Wouter Froyman; Guillermo Gallardo Madueño; Birthe Lemley; Annika Loft; Liliana Mereu; Philippe Morice; Denis Querleu; Antonia Carla Testa; Ignace Vergote; Vincent Vandecaveye; Giovanni Scambia; Christina Fotopoulou
Journal:  Int J Gynecol Cancer       Date:  2021-06-10       Impact factor: 3.437

Review 6.  Tumor microenvironment complexity and therapeutic implications at a glance.

Authors:  Roghayyeh Baghban; Leila Roshangar; Rana Jahanban-Esfahlan; Khaled Seidi; Abbas Ebrahimi-Kalan; Mehdi Jaymand; Saeed Kolahian; Tahereh Javaheri; Peyman Zare
Journal:  Cell Commun Signal       Date:  2020-04-07       Impact factor: 5.712

Review 7.  Novel Epigenetic Biomarkers in Pregnancy-Related Disorders and Cancers.

Authors:  Valentina Karin-Kujundzic; Ida Marija Sola; Nina Predavec; Anamarija Potkonjak; Ema Somen; Pavao Mioc; Alan Serman; Semir Vranic; Ljiljana Serman
Journal:  Cells       Date:  2019-11-18       Impact factor: 6.600
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.